PPD Strengthens Regulatory Consulting And Ophthalmology Expertise
WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced it has appointed Jonca Bull, M.D., in a dual role as vice president of PPD® Consulting, where she will serve as the head of regulatory consulting and as vice president, ophthalmology, within global product development.
“Jonca possesses a wealth of experience in the regulatory arena, including with the FDA and in the pharmaceutical industry”
Bull joined PPD from the U.S. Food and Drug Administration (FDA), where she most recently served as assistant commissioner and director of its Office of Minority Health.
“Jonca possesses a wealth of experience in the regulatory arena, including with the FDA and in the pharmaceutical industry,” said Rob Dow, chief medical officer for PPD. “Her experience working closely with pharmaceutical clients, as well as health and regulatory authorities, will help enhance patient engagement for PPD clients in developing life-changing therapies.”
PPD Consulting provides full drug development design and planning facilities, with broad experience of regulatory guidelines and the drug development process. Along with teams of consulting experts, the global product development teams coordinate multidisciplinary services and insight from therapeutic thought leaders to create customized development strategies to meet client needs.
In the past five years, PPD’s dedicated global ophthalmology team has facilitated more than 65 trials, which have involved more than 9,000 patients and 1,400 investigative sites. The team’s comprehensive services include drug development and consulting in all functional areas of expertise to assist PPD’s clients.
Prior to joining the FDA, Bull was the vice president of U.S. regulatory policy for Novartis, and formerly worked at Genentech as the director of clinical regulatory policy.
Bull earned a bachelor’s degree from Princeton University and a medical degree from Duke University Medical School. She completed her residency in ophthalmology at George Washington University Hospital and is board certified.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and approximately 20,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.